#	Pagina
attuale pagina	/open-h2020/projects/217367/index.html

Opendata, web and dolomites

TETUS SIGNED

Tissue-engineered oral mucosa cells for treatment of urethral strictures

Total Cost €

EC-Contrib. €

Partnership

Views

Outcomes and
results

TETUS project word cloud

Explore the words cloud of the TETUS project. It provides you a very rough idea of what is the project "TETUS" about.

eligible sale complexities clinical marketing commercialisation once 2023 revenue 630 2022 prepares plans tetus requirments 13 authorisation territories 890 150 obtain million mukocell reg market followed reimbursement unmet medical 2021 data 23 ready radical generating country asia financial place strategies cell accelerated respectively

Project "TETUS" data sheet

The following table provides information about the project.

Coordinator	MUKOCELL GMBH Organization address address: OTTO-HAHN-STR 15 city: DORTMUND postcode: 44227 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Germany [DE]
Project website	http://www.mukocell.com
Total cost	2˙630˙270 €
EC max contribution	1˙841˙189 € (70%)
Programme	1. H2020-EU.3. (PRIORITY 'Societal challenges) 2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs) 3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
Code Call	H2020-SMEInst-2018-2020-2
Funding Scheme	SME-2
Starting year	2018
Duration (year-month-day)	from 2018-08-01 to 2020-07-31

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	MUKOCELL GMBH MUKOCELL GMBH Organization address address: OTTO-HAHN-STR 15 city: DORTMUND postcode: 44227 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	DE (DORTMUND)	coordinator	1˙841˙189.00

Map

Project objective

TETUS will address commercialisation complexities related to cell products and prepares MukoCell® for accelerated commercialisation by facilitating an EU-wide Market Authorisation. As MukoCell® addresses an unmet medical need, it is eligible to use an EU-accelerated market access pathway. Once Marketing Authorisation is in place, country-specific reimbursement strategies and market access (financial) plans can be developed that are requirments of for MukoCell® ready to go to market.Therefore, after TETUS, a radical increase in the sale of MukoCell® in the EU is expected in 2021 generating a revenue of €4.630 million followed by €13.890 million and €23.150 million from the market in the EU in 2022 and 2023, respectively. The clinical data produced through TETUS can be used to obtain Market Authorisation in other territories such as US and Asia.

Publications

List of publications.
year	authors and title	journal	last update
2018	Guido Barbagli, Ilgar Akbarov, Axel Heidenreich, Vahudin Zugor, Roberto Olianas, Maurizio Aragona, Giuseppe Romano, Ulf Balsmeyer, Dirk Fahlenkamp, Udo Rebmann, Diana Standhaft, Massimo Lazzeri Anterior Urethroplasty Using a New Tissue Engineered Oral Mucosa Graft: Surgical Techniques and Outcomes published pages: 448-456, ISSN: 0022-5347, DOI: 10.1016/j.juro.2018.02.3102	Journal of Urology 200/2	2019-09-03

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "TETUS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "TETUS" are provided by the European Opendata Portal: CORDIS opendata.